Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.

ABSTRACT:

Introduction

There is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease-specific biomarkers capable of accurately diagnosing mild-moderate stages of AD and Parkinson's disease.

Methods

Sera from 236 subjects, including 50 mild cognitive impairment (MCI) subjects with confirmed low CSF Aβ42 levels, were screened with human protein microarrays to identify potential biomarkers for MCI. Autoantibody biomarker performance was evaluated using Random Forest and Receiver Operating Characteristic curves.

Results

Autoantibody biomarkers can differentiate MCI patients from age-matched and gender-matched controls with an o

SUBMITTER: DeMarshall CA 

PROVIDER: S-EPMC4879649 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature